These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 35281472)
41. Comprehensive analyses of fatty acid metabolism-related lncRNA for ovarian cancer patients. Li M; Yan Y; Liu Y; Zhao J; Guo F; Chen J; Nie L; Zhang Y; Wang Y Sci Rep; 2023 Sep; 13(1):14675. PubMed ID: 37673886 [TBL] [Abstract][Full Text] [Related]
42. Immune-related biomarkers predict the prognosis and immune response of breast cancer based on bioinformatic analysis and machine learning. Zheng X; Ma H; Dong Y; Fang M; Wang J; Xiong X; Liang J; Han M; You A; Yin Q; Huang W Funct Integr Genomics; 2023 Jun; 23(3):201. PubMed ID: 37291471 [TBL] [Abstract][Full Text] [Related]
43. Identification of pathological grade and prognosis-associated lncRNA for ovarian cancer. Chen Y; Bi F; An Y; Yang Q J Cell Biochem; 2019 Sep; 120(9):14444-14454. PubMed ID: 31034644 [TBL] [Abstract][Full Text] [Related]
44. Systematic prediction of key genes for ovarian cancer by co-expression network analysis. Wang M; Wang J; Liu J; Zhu L; Ma H; Zou J; Wu W; Wang K J Cell Mol Med; 2020 Jun; 24(11):6298-6307. PubMed ID: 32319226 [TBL] [Abstract][Full Text] [Related]
45. Integrated analysis of a competing endogenous RNA network reveals an 11-lncRNA prognostic signature in ovarian cancer. Zhang Y; Zhou H; Zhang M; Xing L; Yang C; Xia B; Lou G Aging (Albany NY); 2020 Nov; 12(24):25153-25171. PubMed ID: 33223503 [TBL] [Abstract][Full Text] [Related]
46. Identification of MEG8/miR-378d/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis. Lei J; He ZY; Wang J; Hu M; Zhou P; Lian CL; Hua L; Wu SG; Zhou J Cancer Med; 2021 Apr; 10(8):2924-2939. PubMed ID: 33742531 [TBL] [Abstract][Full Text] [Related]
47. Single-sample gene set enrichment analysis reveals the clinical implications of immune-related genes in ovarian cancer. Gong W; Kuang M; Chen H; Luo Y; You K; Zhang B; Liu Y Front Mol Biosci; 2024; 11():1426274. PubMed ID: 39161779 [TBL] [Abstract][Full Text] [Related]
48. Identification of a novel 10 immune-related genes signature as a prognostic biomarker panel for gastric cancer. Chen T; Yang C; Dou R; Xiong B Cancer Med; 2021 Sep; 10(18):6546-6560. PubMed ID: 34382341 [TBL] [Abstract][Full Text] [Related]
49. Identification of Novel Diagnostic Biomarkers in Prostate Adenocarcinoma Based on the Stromal-Immune Score and Analysis of the WGCNA and ceRNA Network. Zhang T; Wang Y; Dong Y; Liu L; Han Y; Wang H; Wei Q; Xia P; Ma W; Li L Dis Markers; 2022; 2022():1909196. PubMed ID: 35075375 [TBL] [Abstract][Full Text] [Related]
50. Identification and validation of shared genes and key pathways in endometriosis and endometriosis-associated ovarian cancer by weighted gene co-expression network analysis and machine learning algorithms. Du Y; Hu Y; Zhang F; Guan Y; Sheng Y J Obstet Gynaecol Res; 2023 Aug; 49(8):2135-2150. PubMed ID: 37340502 [TBL] [Abstract][Full Text] [Related]
51. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer. Xu F; Liu T; Zhou Z; Zou C; Xu S Front Immunol; 2021; 12():749369. PubMed ID: 34745121 [TBL] [Abstract][Full Text] [Related]
52. Computed Tomography Imaging-Based Radiogenomics Analysis Reveals Hypoxia Patterns and Immunological Characteristics in Ovarian Cancer. Feng S; Xia T; Ge Y; Zhang K; Ji X; Luo S; Shen Y Front Immunol; 2022; 13():868067. PubMed ID: 35418998 [TBL] [Abstract][Full Text] [Related]
53. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer. Peng Y; Wang H; Huang Q; Wu J; Zhang M J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063 [TBL] [Abstract][Full Text] [Related]
54. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis. Li Y; Li L J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725 [TBL] [Abstract][Full Text] [Related]
55. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer. Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X Front Immunol; 2021; 12():725223. PubMed ID: 34484235 [TBL] [Abstract][Full Text] [Related]
56. An EMT-based gene signature enhances the clinical understanding and prognostic prediction of patients with ovarian cancers. Li QJ; Wu ZL; Wang J; Jiang J; Lin B J Ovarian Res; 2023 Mar; 16(1):51. PubMed ID: 36907877 [TBL] [Abstract][Full Text] [Related]
57. Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma. Zhu Y; Zhao Y; Cao Z; Chen Z; Pan W Gene; 2022 Apr; 818():146177. PubMed ID: 35065254 [TBL] [Abstract][Full Text] [Related]
58. A novel immune-related prognostic index for predicting breast cancer overall survival. Yu X; Guo J; Zhou Q; Huang W; Xu C; Long X Breast Cancer; 2021 Mar; 28(2):434-447. PubMed ID: 33146847 [TBL] [Abstract][Full Text] [Related]
59. Identification and Validation of an Energy Metabolism-Related lncRNA-mRNA Signature for Lower-Grade Glioma. Zhao J; Wang L; Wei B Biomed Res Int; 2020; 2020():3708231. PubMed ID: 32802843 [TBL] [Abstract][Full Text] [Related]
60. Association between tumor mutation burden and immune infiltration in ovarian cancer. Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]